Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591)
Hong Kong · Delayed Price · Currency is HKD 44.00
+2.66 (6.43%)
At close: Dec 5, 2025
Guangzhou Innogen Pharmaceutical Group Company Description
Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in development of drugs.
Its products are used for treatment of metabolic diseases, including diabetes, obesity, and MASH; and other major central nervous system diseases.
The company was incorporated in 2014 and is based in Shanghai, China.
Guangzhou Innogen Pharmaceutical Group Co., Ltd
| Country | China |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | Qinghua Wang |
Contact Details
Address: 720 Cai Lun Road Shanghai China | |
| Website | innogenpharm.com |
Stock Details
| Ticker Symbol | 2591 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000071Q7 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Qinghua Wang M.D., Ph.D. | Founder, GM and Executive Chairman |
| Fan Jiang | Vice President, Chief Financial Officer, joint Secretary to the Board and Executive Director |
| Wenjie Xu M.B.A. | Senior Vice President and Executive Director |
| Bing Huang M.S. | Vice President and Executive Director |
| Jin Jin | Joint Company Secretary |
| Suet Ling Sze A.C.I.S., A.C.S., ACIS ACS | Joint Company Secretary |